About
Bradford
  HIV/AIDS
Articles
  Alternative
Therapies
  HIV/AIDS
Videos
  HIV/AIDS
Links
  HIV/AIDS
News

Introduction:
Positively Positive
- Living with HIV
  Out
About
HIV
  Resume/
Curriculum Vitae:
HIV / AIDS Involvements
  Biography   HIV/AIDS
News Archive
HIV/AIDS News spacer.gif spacer.gif
spacer.gif
   
AIDS Awareness Red Ribbon


Cortisol, Cortisone Levels in Hair May Be Indicators of HIV Disease Progression, Study Finds

May 5, 2022

New research shows that cortisol and cortisone levels in the hair of people living with HIV were negatively associated with CD4 count, but not with HIV viral load.

Among Chinese patients living with HIV, hair cortisol and cortisone levels were negatively associated with CD4 count, but not with HIV viral load, according to a study published in BMC Infectious Diseases.

Whereas past research has mostly studied the correlation between acute or short-term glucocorticoid exposure and HIV disease progression, this study focused on long-term exposure and how hair glucocorticoid levels were associated with CD4 count and HIV viral load—2 main markers of HIV disease progression.

After exclusions following the collection of hair samples, a total of 1198 Chinese patients living with HIV who had received combination antiretroviral therapy (cART) were included in the study.

The median age was 38 years and most (64.3%) were male. Most participants were of Han ethnicity, married, and employed, and most did not smoke or drink during the study period and washed their hair less than 4 times per week.

Regarding HIV treatment and viral load, 79.7% of participants were receiving first-line cART, 92.8% were reporting optimal cART adherence (≥95%), and only 2.9% had an HIV viral load of at least 200 copies/mL, indicating that the majority of participants had achieved viral suppression.

Participants were excluded if they:

  • had a linguistic, mental, or physical inability to respond to the assessment questions;
  • had opportunistic infections or endocrine diseases, such as Cushing syndrome;
  • were actively taking hormonal medications or had a known history of illegal drug use; or

  • had chemically treated hair or scalp hair in the posterior vertex was less than 1 cm.

Hair samples were collected by cutting strands from the posterior vertex area as close to the scalp as possible, and then wrapping the hair thatch in foil to transport to the researchers.

“Recently, hair cortisone levels have been served as a useful additional biomarker for assessing long-term glucocorticoid exposure,” the study authors explained. “As well known, circulating cortisol levels are dynamically regulated partially through the activity of the 11β hydroxysteroid dehydrogenase (11β-HSD) enzyme, where cortisol is converted to cortisone by the activity of 11β-HSD type 2 enzyme, and cortisone can be regenerated from cortisol by the activity of 11β-HSD type1 enzyme.”

The authors found that hair cortisol was positively correlated with hair cortisone (r = 0.226; P < .001), and CD4 cell count and HIV viral load were positively correlated (r = 0.070; P < .05).

When comparing hair composition with HIV status, CD4 cell count was negatively correlated with hair cortisol (r = –0.129; P < .001) and cortisone (r = –0.148; P < .001).

When stratifying patients into quartiles based on hair glucocorticoid concentration with other characteristics being controlled, the authors found greater odds of decreased CD4 cell count among those with the highest levels of hair cortisol and cortisone.

Specifically, odds for decreased CD4 cell count were 1.41 (95% CI, 0.99-2.00) and 2.15 (95% CI, 1.51-3.05) times greater among patients in the highest quartile for hair cortisol and cortisone levels, respectively, compared with patients in the lowest quartile for each.

However, there were no significant correlations—positive or negative—observed between hair composition and HIV viral load.

According to the authors, a limitation was using cross-sectional data, as these data did not allow for them to evaluate a causal relationship between hair glucocorticoid levels and HIV disease progression. Additionally, using hair specifically and excluding other forms of glucocorticoid measurements; only using data from people in Guangxi, China; and the lack of data on other factors such as physical exercise were also major limitations.

The authors said future research should focus on the longitudinal relationship of glucocorticoid levels in multiple biological samples as an indicator of HIV disease progression.

Reference

Zhang Q, Li X, Qiao S, Liu S, Zhou Y, Shen Z. The relationship of hair glucocorticoid levels to immunological and virological outcomes in a large cohort of combination antiretroviral therapy treated people living with HIV. BMC Infect Dis. 2022;22(1):268. doi:10.1186/s12879-022-07257-x

###

Contact:

Kim Scaffidi

Paralegal/Contract Manager
o. 732.346.3056
KScaffidi@mjhlifesciences.com
mjhlifesciences.com | twitter | linkedin

Source: https://www.ajmc.com/view/cortisol-cortisone-levels-in-hair-may-be-indicators-of-hiv-disease-progression-study-finds

"Reproduced with permission - The American Journal of Managed Care® (AJMC®)"

The American Journal of Managed Care® (AJMC®)
www.ajmc.com


For more HIV and AIDS News visit...

Positively Positive - Living with HIV/AIDS:
HIV/AIDS News


...positive attitudes are not simply 'moods'

Site Map

Contact Bradford McIntyre.

Web Design by Trevor Uksik
uks.jpg

Copyright © 2003 - 2024 Bradford McIntyre. All rights reserved.

DESIGNED TO CREATE HIV & AIDS AWARENESS

spacer.gif
| Positively Positive
About
Bradford
  HIV/AIDS
Articles
  Alternative
Therapies
  HIV/AIDS
Videos
  HIV/AIDS
Links
  HIV/AIDS
News

Introduction:
Positively Positive
- Living with HIV
  Out
About
HIV
  Resume/
Curriculum Vitae:
HIV / AIDS Involvements
  Biography   HIV/AIDS
News Archive
HIV/AIDS News spacer.gif spacer.gif
spacer.gif
   
AIDS Awareness Red Ribbon


People With HIV at Higher Risk of COVID-19 Infection Even After Vaccination, Study Finds

January 11, 2022

Researchers found that fully vaccinated people with HIV have a 41% higher risk of COVID-19 breakthrough infection compared with people without HIV.

COVID-19 vaccination has been proven effective, but findings from a study by Johns Hopkins University investigators published online as a preprint showed that people living with HIV have an increased risk of breakthrough infections compared with people without HIV.

For people with advanced or untreated HIV, the CDC currently recommends a booster vaccine either 28 days after the second mRNA dose or 2 months after the single Johnson & Johnson (J&J) dose. However, the authors of the study—which has not yet been peer reviewed—argued that recommendations for additional vaccine doses should be expanded to all people living with HIV.

The authors analyzed data from 4 longitudinal cohorts from integrated health systems and academic health centers in the US. They sorted data by vaccination type and by immune or viral suppression status at the time of vaccination. Participants were followed to the date of breakthrough infection, death, disenrollment from the health system, 210 days (7 months) after the date they were fully vaccinated, or until September 30, 2021, whichever occurred first.

After making necessary exclusions due to vaccine mixing within the primary series, a total of 109,599 people were included in the study, with 31,840 participants living with HIV and 77,759 living without HIV. The population was dominantly male (92%) and aged 55 and older (71%). Most (41%) participants were non-Hispanic Black. A small number of participants received the J&J vaccine (6%); most received Pfizer (51%) or Moderna (43%).

“Although we did not match on vaccine type, the distribution of vaccine type by HIV status did not differ by more than 2 percentage points,” the authors noted, adding that 26% of participants with HIV received a booster dose after the primary series compared with only 12% of those without HIV.

The overall incidence rate of breakthrough infections was 35 per 1000 person-years, with a 2.3% incidence of breakthrough infection in the entire population 7 months after being fully vaccinated. Although they still had a relatively low rate of breakthrough infection, people with HIV had a higher incidence (2.8%) compared with people without HIV (2.1%). Incidence rate varied by vaccine type—J&J (3.3%), Pfizer (2.6%), and Moderna (1.7%)—and risk of breakthrough infection was consistently higher for people with HIV.

According to the authors, these findings are consistent with studies showing lower efficacy of the J&J vaccine compared with mRNA vaccines and, further, more breakthrough infections among people with the Pfizer primary series compared with Moderna.

After controlling for HIV status, researchers found a 41% higher risk of COVID-19 breakthrough infection in fully vaccinated people with HIV compared with other groups. Additionally, they found no statistically significant differences in risk when comparing viral loads and CD4 counts among participants with HIV, suggesting all fully vaccinated people with HIV are more susceptible to breakthrough infection.

Among participants with HIV, older age (aged 55-74 years) was linked to decreased risk of breakthrough, while younger age (aged 18-24 years) was linked to increased risk, compared with individuals aged 44 to 54 years. According to the authors, this association may be representative of behavioral changes made to follow COVID-19 guidelines rather than biological factors.

The authors also noted that an association between history of COVID-19 before vaccination and increased risk of breakthrough infection among people with HIV may be connected to the level of exposure or adoption of prevention measures.

“For example, [people with HIV] with increased exposure (perhaps occupational) prior to being fully vaccinated may have had persistent increased exposure post-full vaccination, leading to increased breakthroughs,” they said. “This may also reflect the increased burden of underlying comorbidities among people aging with HIV that increased their vulnerability to COVID-19.”

The authors noted these findings are not necessarily reflective of the total US population living with HIV, as they only included people with health care access in the study.

Reference

Coburn SB, Humes E, Lang R, et al. COVID-19 infections post-vaccination by HIV status in the United States. medRxiv. Preprint published online December 6, 2021. doi:10.1101/2021.12.02.21267182

###

Contact:

Kim Scaffidi

Paralegal/Contract Manager
o. 732.346.3056
KScaffidi@mjhlifesciences.com
mjhlifesciences.com | twitter | linkedin

Source: https://www.ajmc.com/view/transplant-equity-called-for-among-persons-living-with-hiv

"Reproduced with permission - The American Journal of Managed Care® (AJMC®)"

The American Journal of Managed Care® (AJMC®)
www.ajmc.com


For more HIV and AIDS News visit...

Positively Positive - Living with HIV/AIDS:
HIV/AIDS News


...positive attitudes are not simply 'moods'

Site Map

Contact Bradford McIntyre.

Web Design by Trevor Uksik
uks.jpg

Copyright © 2003-2022 Bradford McIntyre. All rights reserved.

DESIGNED TO CREATE HIV & AIDS AWARENESS

spacer.gif